This work provides the first proof of principle that a BRG1 inhibitorcan directly inhibit cancer cell proliferation as well as complement thechemotherapeutic activities of clinically relevant drugs currently used forpatient treatment. The gene discussed is SMARCA4; the disease is cancer.